186 related articles for article (PubMed ID: 24251310)
1. Are the 18F-FDG positron emission tomography/computed tomography findings in bronchopulmonary carcinoid tumors different than expected?
Alpay L; Lacin T; Kanbur S; Kiral H; Ersoz E; Bayram S; Dogruyol T; Baysungur V; Yalcinkaya I
Hell J Nucl Med; 2013; 16(3):213-7. PubMed ID: 24251310
[TBL] [Abstract][Full Text] [Related]
2. Growth of a solitary pulmonary nodule after 6years diagnosed as oncocytic carcinoid tumour with a high 18-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography-computed tomography (PET-CT).
Turan O; Ozdogan O; Gurel D; Onen A; Kargi A; Sevinc C
Clin Respir J; 2013 Jan; 7(1):e1-5. PubMed ID: 22129499
[TBL] [Abstract][Full Text] [Related]
3. Bronchogenic carcinoid tumours that are 18F-fluorodeoxyglucose avid on positron emission tomography.
Hunt BM; Horton MP; Vallières E
Eur J Cardiothorac Surg; 2014 Mar; 45(3):527-30. PubMed ID: 24047710
[TBL] [Abstract][Full Text] [Related]
4. Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumors.
Gasparri R; Rezende GC; Fazio N; Maisonneuve P; Brambilla D; Travaini LL; Paganelli G; Petrella F; Galetta D; Spaggiari L
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):446-54. PubMed ID: 26416036
[TBL] [Abstract][Full Text] [Related]
5. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
6. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid.
Lococo F; Perotti G; Cardillo G; De Waure C; Filice A; Graziano P; Rossi G; Sgarbi G; Stefanelli A; Giordano A; Granone P; Rindi G; Versari A; Rufini V
Clin Nucl Med; 2015 Mar; 40(3):e183-9. PubMed ID: 25608152
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT Diagnosis of Bronchopulmonary Carcinoids Versus Pulmonary Hamartomas.
Uhlén N; Grundberg O; Jacobsson H; Sundin A; Dobra K; Sánchez-Crespo A; Axelsson R; Kölbeck KG
Clin Nucl Med; 2016 Apr; 41(4):263-7. PubMed ID: 26828139
[TBL] [Abstract][Full Text] [Related]
8. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours.
Krüger S; Buck AK; Blumstein NM; Pauls S; Schelzig H; Kropf C; Schumann C; Mottaghy FM; Hombach V; Reske SN
J Intern Med; 2006 Dec; 260(6):545-50. PubMed ID: 17116005
[TBL] [Abstract][Full Text] [Related]
9. Oncocytic carcinoid tumor of the lung with intense F-18 fluorodeoxyglucose (FDG) uptake in positron emission tomography-computed tomography (PET/CT).
Tanabe Y; Sugawara Y; Nishimura R; Hosokawa K; Kajihara M; Shimizu T; Takahashi T; Sakai S; Sawada S; Yamashita M; Ohtani H
Ann Nucl Med; 2013 Oct; 27(8):781-5. PubMed ID: 23757317
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
[TBL] [Abstract][Full Text] [Related]
11. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
12. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
Daniels CE; Lowe VJ; Aubry MC; Allen MS; Jett JR
Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of the predictive value of mid-treatment 18F-FDG-PET/CT scans in pediatric lymphomas and undefined criteria of abnormality in quantitative analysis.
Zhu HJ; Halkar R; Alavi A; Goris ML
Hell J Nucl Med; 2013; 16(3):169-74. PubMed ID: 24137579
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for N2 metastasis in patients with non-small-cell lung cancer: multivariate analyses of 18F-FDG PET/CT data.
Su M; Li Y; Li F; Li L; Tian R
Nucl Med Commun; 2014 Sep; 35(9):916-21. PubMed ID: 24785010
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
16. Surgical outcomes in 13 patients with bronchopulmonary carcinoid tumors including one recurrent oncocytic carcinoid tumor.
Ueno T; Maki Y; Sugimoto R; Yamashita M; Nakata K; Sugawara Y; Nishimura R; Teramoto N
Gen Thorac Cardiovasc Surg; 2019 May; 67(5):486-489. PubMed ID: 29971648
[TBL] [Abstract][Full Text] [Related]
17. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
18. Limited Prognostic Value of SUV max Measured by F-18 FDG PET/CT in Newly Diagnosed Small Cell Lung Cancer Patients.
Kim SJ; Chang S
Oncol Res Treat; 2015; 38(11):577-85. PubMed ID: 26599271
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
20. Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?
Koolen BB; Elshof LE; Loo CE; Wesseling J; Vrancken Peeters MJ; Vogel WV; Rutgers EJ; Valdés Olmos RA
Eur J Radiol; 2013 Dec; 82(12):2353-8. PubMed ID: 23998705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
